- Report
- May 2025
- 190 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- August 2024
- 141 Pages
Global
From €2686EUR$2,999USD£2,290GBP
- Report
- May 2025
- 191 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- March 2022
- 376 Pages
Global
From €4298EUR$4,799USD£3,664GBP
- Report
- February 2023
- 90 Pages
Global
From €4434EUR$4,950USD£3,779GBP
- Report
- November 2023
- 171 Pages
Global
From €2239EUR$2,500USD£1,909GBP
- Report
- April 2023
- 97 Pages
Global
From €3500EUR$4,186USD£3,088GBP
- Book
- September 2017
- 632 Pages
Pharmaceutical Continuous Manufacturing (PCM) is a process of manufacturing pharmaceuticals that involves the continuous production of drug products. It is an alternative to traditional batch manufacturing, which involves the production of drug products in discrete batches. PCM is a more efficient and cost-effective method of production, as it eliminates the need for multiple production steps and reduces the amount of time and resources required for production. PCM also allows for greater control over the production process, as it allows for the monitoring of the process in real-time. This allows for the detection of any issues that may arise during production, allowing for a more efficient and cost-effective production process.
PCM is becoming increasingly popular in the pharmaceutical manufacturing industry, as it offers a number of advantages over traditional batch manufacturing. Companies in the PCM market include GEA, Glatt, Bosch, and Siemens. Show Less Read more